CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:NK-cell post-transplant lymphoproliferative disease successfully treated by second allogenic hematopoietic stem cell transplantation in chronic active Epstein-Barr virus infection.
NK-cell post-transplant lymphoproliferative disease successfully treated by second allogenic hematopoietic stem cell transplantation in chronic active Epstein-Barr virus infection.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
慢性活动性Epstein-Barr病毒感染(CAEBV)是一种由EB病毒(EBV)引起的系统性T细胞或自然杀伤(NK)细胞淋巴增殖性疾病(LPD)。异基因造血干细胞移植(HSCT)是CAEBV唯一的根治性治疗,但仍可能复发。复发通常被认为与受者来源的CAEBV细胞增殖有关。本文报告一例病例:一名41岁女性因CAEBV接受HLA匹配的同胞供者首次异基因HSCT后,发生供者来源的CAEBV样NK细胞移植后淋巴增殖性疾病(PTLD)。随后接受HLA匹配的无关供者第二次HSCT,疾病得到控制,但仍持续检测到第二位供者来源细胞感染EBV。尽管CAEBV及CAEBV样NK细胞PTLD的发病机制尚未得到详细阐明,本病例提示,包括家族因素在内的宿主遗传因素可能参与疾病发生。
Chronic active Epstein-Barr virus infection (CAEBV) is a systemic T- or NK-lymphoproliferative disorder (LPD) caused by EBV. Allogenic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for CAEBV, but relapse sometimes occurs. Relapse is generally attributed to proliferation of recipient-derived CAEBV cells.
We herein report a case of donor-derived CAEBV-like NK-cell post-transplant lymphoproliferative disease (PTLD) in a 41-year-old female after the first allogenic HSCT for CAEBV from an HLA-matched sibling donor. A second HSCT from an HLA-matched unrelated donor successfully controlled the disease, but EBV infection of cells derived from the second donor continued to be detected.
Although the mechanisms underlying CAEBV and CAEBV-like NK-cell PTLD have not yet been elucidated in detail, the findings of the present case imply that host genetic factors, including familial factors, may be important in disease development.
MEMBER ACCOUNT
登录成功会直接打开下一页。